Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA

Author:

Plaza Vicente1ORCID,Domínguez-Ortega Javier2ORCID,González-Segura Alsina Diego3,Lo Re Daniele4ORCID,Sicras-Mainar Antoni5

Affiliation:

1. Servicio de Neumología y Alergia, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain

2. Department of Allergy, La Paz University Hospital, Institute for Health Research (IdiPAZ), 28046 Madrid, Spain

3. Chiesi España, 08908 Barcelona, Spain

4. Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, Universidad de Granada, 18071 Granada, Spain

5. Atrys Health, SA, 28002 Madrid, Spain

Abstract

Introduction: Adding LAMA to LABA/ICS is recommended to improve control in patients with persistent asthma. Methods: This observational, retrospective, before-and-after study considered patients diagnosed with asthma who started LABA/ICS + LAMA treatment (triple therapy, TT) between 1 January 2017 and 31 December 2018 and had been treated with LABA/ICS (dual therapy, DT) in the year before. Changes in lung function and exacerbation rates, healthcare resource utilization, and healthcare and non-healthcare costs (€2019) were estimated in patients with asthma in clinical practices in Spain. Data from computerized medical records from seven Spanish regions were collected ±1 year of LAMA addition. Results: 4740 patients (64.1 years old [SD: 16.3]) were included. TT reduced the incidence of exacerbations by 16.7% (p < 0.044) and the number of patients with exacerbations by 8.5% (p < 0.001) compared to previous DT. The rate of patients with severe exacerbations requiring systemic corticosteroids and their hospitalization rates significantly decreased by 22.5% and 29.5%. TT significantly improved FEV1, FVC, and FEV1/FVC, saving €571/patient for society. Younger patients with asthma (18–44 years old) and patients with severe asthma (FEV1 < 60%) performed better upon the initiation of TT. Conclusions: TT reduced asthma exacerbations, improved lung function and reduced healthcare costs vs. DT, particularly in patients requiring systemic corticosteroids to treat severe exacerbations.

Funder

Chiesi

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference48 articles.

1. Global Initiative for Asthma (GINA) (2023, April 19). Global Strategy for Asthma Management. Available online: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.

2. Ntontsi, P., Photiades, A., Zervas, E., Xanthou, G., and Samitas, K. (2021). Genetics and Epigenetics in Asthma. Int. J. Mol. Sci., 22.

3. Epigenetics and Social Inequalities in Asthma and Allergy;Clausing;J. Allergy Clin. Immunol.,2023

4. Prevalence and Attributable Health Burden of Chronic Respiratory Diseases, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017;Soriano;Lancet Respir. Med.,2020

5. Gibson, G.J., Loddenkemper, R., Sibille, Y., Lundbäck, B., and Fletcher, M. (2023). Lung Health in Europe. Facts & Figures: A Better Understanding of Lung Disease and Respiratory Care in Europe, European Lung Foundation (ELF).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3